Synthekine further developed this concept, focusing on three key aspects: (1) IL-18 can enhance both innate and adaptive anti-cancer immune responses through signaling across a wide range of cells, (2) IL-18’s proinflammatory activity can counteract the tumor microenvironment’s immunosuppressive state, and (3) IL-18 has shown good tolerance as a single agent in clinical trials. Here, IL18 is linked to cancer.